Ascendis Pharma A/S has announced the Australian registration of SKYTROFA® (lonapegsomatropin) by the Therapeutic Goods Administration $(TGA)$ as a once-weekly injectable therapy for paediatric growth hormone deficiency. This approval is a significant milestone for Ascendis Pharma and its distribution partner, Specialised Therapeutics $(ST)$, marking the second endocrinology therapy registered in Australia by ST. SKYTROFA is designed to treat growth failure in children and adolescents aged 3 to 18 due to insufficient endogenous growth hormone secretion, aiming to improve not only stature but also address the physical and psychosocial impacts associated with the condition. This approval follows prior endorsements by the US FDA and the European Medicines Agency.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。